Exposure report
SCHD vs VYM
Compare what the funds own and how their adjusted prices behaved. Every result below identifies the observed period and the amount of holdings data represented.
Reported exposure intersection
Price Performance
Historical price comparison over 3M
Latest adjusted-close observations: SCHD 2026-08-31 · VYM 2026-08-31.
Performance Comparison
⚠️Risk Metrics
Interpretation:
- Lower volatility = smoother ride
- Higher Sharpe/Sortino = better risk-adjusted returns
- Smaller max drawdown = less worst-case pain
- Beta > 1 = more volatile than S&P 500
Risk metrics use the available common observations, a 4% annual risk-free assumption and SPY as the beta benchmark.
Shared reported holdings
2 positions account for a known minimum overlap of 4.5%.
Top Shared Holdings
| # | Stock | SCHD Weight | VYM Weight | Overlap |
|---|---|---|---|---|
| 1 | ABBV AbbVie Inc | 3.45% | 2.38% | 2.38% |
| 2 | MRK Merck & Co | 3.85% | 2.15% | 2.15% |
Overlap by Sector
Showing top 5 sectors by overlap contribution
Largest positions reported only in SCHD
| Symbol | Name | Weight |
|---|---|---|
| PEP | PepsiCo Inc | 4.45% |
| KO | Coca-Cola Co | 4.25% |
| CSCO | Cisco Systems | 4.05% |
| PFE | Pfizer Inc | 3.65% |
| VZ | Verizon Communications | 3.35% |
Largest positions reported only in VYM
| Symbol | Name | Weight |
|---|---|---|
| AVGO | Broadcom Inc | 4.52% |
| JPM | JPMorgan Chase & Co | 3.82% |
| XOM | Exxon Mobil Corp | 3.24% |
| PG | Procter & Gamble Co | 2.65% |
| HD | Home Depot Inc | 2.58% |
Price Correlation
Methodology
What this report can and cannot establish
Known overlap: for each shared security, we add the smaller reported fund weight. Reported weights remain in their original scale.
Possible overlap: the upper bound adds only the smaller unreported portion. It is uncertainty, not an estimate that the missing positions actually match.
Prices: returns and risk use adjusted-close observations, so distributions and splits are reflected when supplied by the market-data source.
No recommendation: EigenDex does not assign a winner. Costs, tax treatment, liquidity and mandate should be verified with each issuer before acting.